U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07396467) titled 'Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis' on Feb. 01.
Brief Summary: This retrospective observational study will evaluate immune checkpoint inhibitor (ICI)-related outcomes in lung cancer patients with concomitant pulmonary fibrosis/interstitial lung disease (ILD) and determine how fibrosis/ILD modifies immunotherapy effectiveness and safety. We will characterize the clinical, radiographic, pathological, and molecular features of lung cancer with ILD and examine their associations with ICI response and survival. A comparator cohort of lung cancer patients without radiographic ILD from the same insti...